Forbion chooses Amphista as first protein degradation investment, co-leading $53M series B

After surveying the landscape of targeted protein degradation companies, Forbion Capital Partners homed in on U.K.-based Amphista as its first investment in the space, co-leading Wednesday’s $53 million series B round alongside Gilde Healthcare Partners. 

“We had been looking for what we call the second wave of targeted protein degradation, which adds upon what we know works but also addresses some of the challenges in the field,” Forbion’s Rogier Rooswinkel told BioCentury. ...